Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Evolocumab公司 医学 动脉粥样硬化性心血管疾病 内科学 疾病 心脏病学 期限(时间) 重症监护医学 胆固醇 载脂蛋白B 物理 量子力学 载脂蛋白A1
作者
Michelle L. O’Donoghue,Robert P. Giugliano,Stephen D. Wiviott,Dan Atar,Anthony Keech,Julia Kuder,Canqing Yu,Sabina A. Murphy,Jose H. Flores‐Arredondo,J. Antonio G. López,Mary Elliott‐Davey,Bei Wang,Maria Laura Monsalvo,Siddique Abbasi,Marc S. Sabatine
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:146 (15): 1109-1119 被引量:247
标识
DOI:10.1161/circulationaha.122.061620
摘要

Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was safe and well tolerated over a median of 2.2 years of follow-up. However, large-scale, long-term data are lacking. Methods: The parent FOURIER trial randomized 27 564 patients with atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on statin to evolocumab versus placebo. Patients completing FOURIER at participating sites were eligible to receive evolocumab in 2 open-label extension studies (FOURIER-OLE [FOURIER Open-Label Extension]) in the United States and Europe; primary analyses were pooled across studies. The primary end point was the incidence of adverse events. Lipid values and major adverse cardiovascular events were prospectively collected. Results: A total of 6635 patients were enrolled in FOURIER-OLE (3355 randomized to evolocumab and 3280 to placebo in the parent study). Median follow-up in FOURIER-OLE was 5.0 years; maximum exposure to evolocumab in parent plus FOURIER-OLE was 8.4 years. At 12 weeks in FOURIER-OLE, median LDL-C was 30 mg/dL, and 63.2% of patients achieved LDL-C <40 mg/dL on evolocumab. Incidences of serious adverse events, muscle-related events, new-onset diabetes, hemorrhagic stroke, and neurocognitive events with evolocumab long term did not exceed those for placebo-treated patients during the parent study and did not increase over time. During the FOURIER-OLE follow-up period, patients originally randomized in the parent trial to evolocumab versus placebo had a 15% lower risk of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization (hazard ratio, 0.85 [95% CI, 0.75–0.96]; P =0.008); a 20% lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80 [95% CI, 0.68–0.93]; P =0.003); and a 23% lower risk of cardiovascular death (hazard ratio, 0.77 [95% CI, 0.60–0.99]; P =0.04). Conclusions: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02867813 and NCT03080935.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
SciGPT应助科研通管家采纳,获得10
7秒前
背后海亦发布了新的文献求助10
14秒前
慕青应助沈万熙采纳,获得10
15秒前
BCKT完成签到,获得积分10
17秒前
badbaby完成签到 ,获得积分10
17秒前
方圆完成签到 ,获得积分10
19秒前
29秒前
无奈的书琴完成签到 ,获得积分10
32秒前
42秒前
数乱了梨花完成签到 ,获得积分10
47秒前
背后海亦发布了新的文献求助10
47秒前
ACMI完成签到,获得积分10
49秒前
不秃燃的小老弟完成签到 ,获得积分10
52秒前
朱婷完成签到 ,获得积分10
53秒前
小白完成签到 ,获得积分10
54秒前
谢陈完成签到 ,获得积分10
57秒前
从容的水壶完成签到 ,获得积分10
1分钟前
xy完成签到 ,获得积分10
1分钟前
千玺的小粉丝儿完成签到,获得积分10
1分钟前
CHENXIN532完成签到,获得积分10
1分钟前
Spice完成签到 ,获得积分10
1分钟前
喵了个咪完成签到 ,获得积分10
1分钟前
1分钟前
fuws完成签到 ,获得积分10
1分钟前
玺青一生完成签到 ,获得积分10
1分钟前
小新完成签到 ,获得积分10
1分钟前
蛋妮完成签到 ,获得积分10
1分钟前
lilili发布了新的文献求助10
1分钟前
gmc完成签到 ,获得积分10
1分钟前
科研小白完成签到,获得积分10
1分钟前
安子完成签到 ,获得积分10
1分钟前
笑点低的铁身完成签到 ,获得积分10
1分钟前
JayChou完成签到,获得积分10
1分钟前
小静完成签到 ,获得积分10
1分钟前
沈万熙完成签到,获得积分10
1分钟前
奈思完成签到 ,获得积分10
2分钟前
lilili完成签到,获得积分10
2分钟前
婉莹完成签到 ,获得积分0
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513358
关于积分的说明 11167340
捐赠科研通 3248714
什么是DOI,文献DOI怎么找? 1794453
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804664